In today's Traders Exclusive update, George Tkaczuk provides an equity market overview and offers up three new potential trading setups. The Russell 2,000 is lagging the major indexes at this juncture, which is important to note because the small caps were the first group to correct and the first group to bottom in September and October. The 1,183 level will be a key pivot area for the Russell 2,000. Leading sectors of the market include medical, semiconductors, certain areas of retail, and transports. Within medical, there are three biotech stocks of note which might have significant upside. A word of caution, in that these stocks currently have no earnings and their valuations are contingent on the approval of blockbuster drugs. Acadia Pharmaceuticals (ACAD) is one with a promising Alzheimer's drug in the pipeline, and the stock is ready to breakout to new highs. $29-30 is a key level to look to accumulate. ZS Pharma (ZSPH) has a drug for hyperkalemia and the $43 level looks to be an entry. Finally, Opthotech (OPHT) is developing a drug for macular degeneration with very favorable results, and the stock is breaking out at the $44-46 level.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.